arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

MapLight Therapeutics, Inc.

MPLT
$10.76 ▼ -0.11 (-1.01%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

MapLight Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $93.4M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -29.1% ↘
FCF / Share $-15.97 ↗
Trailing P/E —
Price / Book 1.0x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Sep 23, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-161.15M
↓ -107.7% —
FCF / Share Free cash flow per share
$-15.97
↑ +85.2% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
21
Cash Quality ↓
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 3 years · 11 quarters